Drug development company Medivir AB (Nasdaq Stockholm:MVIR) on Monday announced a research collaboration with the Drug Discovery and Development Platform (DDD) and SciLifeLab to find potential inhibitors of the main protease of SARS CoV-2.
DDD has access to Medivir's unique proprietary protease-targeted compound library to identify putative inhibitors and evaluate active compounds as potential drug development candidates. Data for up to 100 top-inhibitors will be released on-line and will be freely available for drug development to combat Covid-19. The essential non-structural protein, Mpro, is reportedly required for virus replication.
This COVID-19 research programme is reportedly led by Kristian Sandberg, associate professor at Uppsala University, co-director of SciLifeLab's DDD Platform and principal investigator of the project Nevermore COVID. The project is part of the national COVID-19 research program at SciLifeLab, which is funded by Knut and Alice Wallenberg Foundation with a total of SEK50m.
(EUR1=SEK10.4775)
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients